Anti-Staphylococcus aureus alpha-hemolysin antibody - China Medical System/Trinomab Biotech
Alternative Names: Fully Human Anti-SA Hlα Antibody - China Medical System; Fully Human Anti-SA Hlα Antibody - Trinomab; Fully Human Hlα Antibody – TrinomabLatest Information Update: 03 May 2021
At a glance
- Originator Trinomab Biotech
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Hemolysin protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Staphylococcal infections
Most Recent Events
- 18 Apr 2021 China Medical System - Trinomab Biotech (JV) acquires Anti-staphylococcus aureus alpha-hemolysin antibody from Trinomab Biotech
- 18 Apr 2021 Preclinical trials in Staphylococcal infections in China (Parenteral)
- 13 Nov 2019 Trinomab Biotech has patent pending for antibody against staphylococcus aureus α-hemolysin and uses thereof in World